Ruxolitinib and Methylprednisolone as a First-line Treatment for Macrophage Activation Syndrome
Status:
Not yet recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
The present study was a single-center, prospective, non-comparative in which macrophage
activation syndrome patients were selected as the main subjects to evaluate the effect and
safety of Ruxolitinib and methylprednisolone regimens as the first-line therapy .